These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C, McCluggage WG. Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603 [Abstract] [Full Text] [Related]
23. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Brustmann H. Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981 [Abstract] [Full Text] [Related]
29. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma. Chen X, Wang X, Wei X, Wang J. J Ovarian Res; 2016 Nov 25; 9(1):83. PubMed ID: 27887627 [Abstract] [Full Text] [Related]
36. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H. Hum Pathol; 2019 Mar 25; 85():299-308. PubMed ID: 30428389 [Abstract] [Full Text] [Related]
37. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG. Pathology; 2011 Aug 25; 43(5):420-32. PubMed ID: 21716157 [Abstract] [Full Text] [Related]
38. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Int J Gynecol Pathol; 2007 Oct 25; 26(4):404-9. PubMed ID: 17885490 [Abstract] [Full Text] [Related]